Loading…
Modest effect on stress and anxiety. Telomere and biological-age claims overrun what trials can show.
Mindfulness shows reliable but modest stress-marker improvements; biological-age claims are not yet supported.
Our read is Partially Supported. The core mechanism holds and the direction is right, but the popular framing tends to overrun what the trials actually show. With a limited evidence base (58/100) and a working majority (66% consensus), meditating daily is reasonable for the right person at $0/month — just calibrate the expectation to the data, not the marketing.
Pulled the public claims about meditating daily from proponents on file (a tracked voice) and weighed them against the more cautious voices in the field, then cross-checked each against the primary trial and cohort literature and the prevailing clinical guidance. We grade the claim against what the human evidence actually supports, not against how confidently it is stated.
Downside risk on meditating daily is low at sensible doses, but low risk is not no risk: individual response varies, and a low-risk intervention is still only worth it if the benefit is real.
A large, long-duration RCT in a general population that either confirms a hard-outcome benefit or shows the effect washes out once it is properly controlled.
Mechanistic and trial evidence converge on a real, replicable effect.
The intervention improves the primary outcome at standard doses in healthy adults.
Benefits hold across the populations where it's been tested.
Mechanistic and trial evidence converge on a real, replicable effect.
Mechanistic and trial evidence converge on a real, replicable effect.
Confounding and publication bias inflate the apparent benefit.
Animal-model results don't translate to the human protocol being recommended.
The headline effect shrinks once you account for trial quality.
Most of the support comes from short or small studies.
Most of the support comes from short or small studies.